CEPI partners with Themis to advance vaccines against Lassa fever and MERS

6. March 2018

|In Portfolio News

|By eazee-designstudio

Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak.